Report details commitment to understanding, monitoring, and managing social and environmental responsibilities.
RADNOR, Pa. — 2024年10月23日 – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in model-informed drug development (MIDD), today announced that it has issued its 2024 environmental, social and governance (ESG) report. The report outlines Certara’s approach to a responsible ESG framework across four pillars: health and social impact of software and services; people and culture; corporate governance and compliance; and environmental impact.
“Our mission is to transform drug development and accelerate medicines to patients through biosimulation software and services. Equally important is how we achieve this goal—with integrity, ethics, and responsibility,” said Certara’s CEO William Feehery, Ph.D. “Together with our clients, we can be proud of what we’ve accomplished, and how we’ve done it.”
Certara 2024 ESG Report Highlights
- Introduced 32 new software applications and updates with R&D investment of $34.1M (10% of revenue) in 2023.
- Worked with nearly 2,400 life sciences companies and academic institutions and have collaborated on more than 8,000 customer projects in the last decade.
- Greenhouse gas emissions were reduced by 7%*
- 23 global regulatory authorities license Certara’s biosimulation software to evaluate the safety and efficacy of new medicines.
- 12 Certara scientists recognized in the top 2% of cited scientists based on metrics published by Elsevier and Stanford University in 2024.
- Certified as Great Place To Work® for three years in a row and named a Fortune Best Workplace in Biopharma
- Recognized by the Forum of Executive Women as a 2024 Champion of Board Diversity in Philadelphia
Certara’s ESG Report is available here: https://www.certara.com/company/responsibility/ The ESG Report was published in October 2024 and reflects data and information as of the respective dates set forth therein.
*Measures were captured and reported by an external sustainability advisor from 2022 to 2023. Emissions measures are Scopes 1 through 3 including direct, upstream and downstream measures.
サターラについて
サターラは、モデリング＆シミュレーション・ソフトウェアと技術を用いて、従来の創薬・開発を変革し、医薬品をよりスピーディーに患者さんに届けることをミッションとしています。製薬、教育機関、規制当局のお客様 2,400人以上、66ヵ国にてサターラの技術やサービスが活用されています。詳細は弊社ホームページをご覧ください。
Certara Contact:
Sheila Rocchio
sheila.rocchio@certara.com
Media Contact:
赤津笑美 (emi.akatsu@certara.com)
certara@pancomm.com
